{
    "xml": "<topic id=\"PHP3492\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/tobramycin\" basename=\"tobramycin\" title=\"TOBRAMYCIN\">\n<title>TOBRAMYCIN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_136\" namespace=\"/interactions/list-of-drug-interactions/antibacterials/aminoglycosides/tobramycin\">Tobramycin</xref>\n</p>\n<data name=\"vtmid\">89695009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_296174173\" title=\"Aminoglycosides\">Aminoglycosides</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34544\" title=\"AMINOGLYCOSIDES\" namespace=\"/drug-classes/aminoglycosides\">AMINOGLYCOSIDES</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP39475\" outputclass=\"indicationsAndDose\" rev=\"1.40\" parent=\"/drugs/tobramycin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Local treatment of infections</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">To the eye</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;17 years</p>\n<p>Apply twice daily for 6&#8211;8 days.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Apply twice daily for 6&#8211;8 days.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Local treatment of infections (severe infection)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">To the eye</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;17 years</p>\n<p>Apply 4 times a day for first day, then apply twice daily for 5&#8211;7 days.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Apply 4 times a day for first day, then apply twice daily for 5&#8211;7 days.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Septicaemia</p>\n<p outputclass=\"therapeuticIndication\">Meningitis and other CNS infections</p>\n<p outputclass=\"therapeuticIndication\">Biliary-tract infection</p>\n<p outputclass=\"therapeuticIndication\">Acute pyelonephritis or prostatitis</p>\n<p outputclass=\"therapeuticIndication\">Pneumonia in hospital patients</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection or by slow intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>3&#8239;mg/kg daily in 3 divided doses; increased if necessary up to 5&#8239;mg/kg daily in 3&#8211;4 divided doses, increased dose used in severe infection; dose to be reduced back to 3&#8239;mg/kg as soon as clinically indicated.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Urinary-tract infection</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2&#8211;3&#8239;mg/kg for 1 dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Chronic <ph outputclass=\"organism\">\n<i>Pseudomonas aeruginosa</i>\n</ph> infection in patients with cystic fibrosis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By inhalation of nebulised solution</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>300&#8239;mg every 12&#8239;hours for 28 days, subsequent courses repeated after 28-day interval without tobramycin nebuliser solution.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By inhalation of powder</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>112&#8239;mg every 12&#8239;hours for 28 days, subsequent courses repeated after 28-day interval without tobramycin inhalation powder.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"extremesOfBodyWeight\">\n<title>Doses at extremes of body-weight</title>\n<p>To avoid excessive dosage in obese patients, use ideal weight for height to calculate parental dose and monitor serum-tobramycin concentration closely.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39538\" outputclass=\"cautions\" rev=\"1.7\" parent=\"/drugs/tobramycin\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<sectiondiv outputclass=\"additionalCautions\">\n<sectiondiv outputclass=\"cautionsOrContraindicationsWithRoutes\">\n<p outputclass=\"title\">When used by inhalation</p>\n<p>\n<ph outputclass=\"caution\">severe haemoptysis&#8212;risk of further haemorrhage</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39418\" outputclass=\"sideEffects\" rev=\"1.19\" parent=\"/drugs/tobramycin\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"specificSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">With intramuscular use</p>\n<p>\n<ph outputclass=\"sideEffect\">rash</ph> (in adults)</p>\n</sectiondiv>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">With intravenous use</p>\n<p>\n<ph outputclass=\"sideEffect\">rash</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">When used by inhalation</p>\n<p>\n<ph outputclass=\"sideEffect\">bronchospasm</ph>; <ph outputclass=\"sideEffect\">cough (more frequent by inhalation of powder)</ph>; <ph outputclass=\"sideEffect\">dysphonia</ph>; <ph outputclass=\"sideEffect\">epistaxis</ph>; <ph outputclass=\"sideEffect\">haemoptysis</ph>; <ph outputclass=\"sideEffect\">laryngitis</ph>; <ph outputclass=\"sideEffect\">mouth ulcers</ph>; <ph outputclass=\"sideEffect\">pharyngitis</ph>; <ph outputclass=\"sideEffect\">salivary hypersecretion</ph>; <ph outputclass=\"sideEffect\">taste disturbances</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39391\" outputclass=\"monitoringRequirements\" parent=\"/drugs/tobramycin\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"therapeuticDrugMonitoring\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in neonates</p>\n<p>\n<i>Extended interval dose regimen in neonates</i>: pre-dose (&#8216;trough&#8217;) concentration should be less than 2&#8239;mg/litre.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in children</p>\n<p>\n<i>Once daily dose regimen</i>: pre-dose (&#8216;trough&#8217;) concentration should be less than 1&#8239;mg/litre.</p>\n<p>\n<i>Multiple daily dose regimen</i>: one-hour (&#8216;peak&#8217;) serum concentration should not exceed 10&#8239;mg/litre (8&#8211;12&#8239;mg/litre in cystic fibrosis); pre-dose (&#8216;trough&#8217;) concentration should be less than 2&#8239;mg/litre.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intramuscular</ph> use or <ph outputclass=\"route\">intravenous</ph> use in adults</p>\n<p>One-hour (&#8216;peak&#8217;) serum concentration should not exceed 10&#8239;mg/litre; pre-dose (&#8216;trough&#8217;) concentration should be less than 2&#8239;mg/litre.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph>\n</p>\n<p>Measure lung function before and after initial dose of tobramycin and monitor for bronchospasm; if bronchospasm occurs in a patient not using a bronchodilator, repeat test using bronchodilator.</p>\n<p>Monitor renal function before treatment and then annually.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39551\" outputclass=\"directionsForAdministration\" rev=\"1.14\" parent=\"/drugs/tobramycin\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in children</p>\n<p>For <i>intravenous infusion</i>, dilute with Glucose 5% or Sodium Chloride 0.9%; give over 20&#8211;60 minutes.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in adults</p>\n<p>For <i>intravenous infusion</i> (<i>Nebcin</i>\n<tm tmtype=\"reg\"/>); intermittent or via drip tubing in Glucose 5% or Sodium chloride 0.9%.</p>\n<p>For adult intermittent infusion suggested volume 50&#8211;100&#8239;mL given over 20&#8211;60 minutes.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph>\n</p>\n<p>Other inhaled drugs should be administered before tobramycin.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58288\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.11\" parent=\"/drugs/tobramycin\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use or when used by <ph outputclass=\"route\">inhalation</ph> in children</p>\n<p>Local guidelines may vary in dosing advice provided.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39450\" outputclass=\"patientAndCarerAdvice\" rev=\"1.10\" parent=\"/drugs/tobramycin\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph>\n</p>\n<p>Patient counselling is advised for Tobramycin dry powder for inhalation (administration).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39371\" outputclass=\"nationalFunding\" rev=\"1.18\" parent=\"/drugs/tobramycin\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA276</p>\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph>\r\n</p>\r\n<p outputclass=\"title\">Tobramycin by dry powder inhalation for pseudomonal lung infection in cystic fibrosis (March 2013)</p>\r\n<p>Tobramycin dry powder for inhalation is recommended for chronic pulmonary infection caused by <ph outputclass=\"organism\">\r\n<i>Pseudomonas aeruginosa</i>\r\n</ph> in patients with cystic fibrosis only if there is an inadequate response to colistimethate sodium, or if colistimethate sodium cannot be used because of contra-indications or intolerance. The manufacturer must provide tobramycin dry powder for inhalation at the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS.</p>\r\n<p>Patients currently receiving tobramycin dry powder for inhalation can continue treatment until they and their clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA276\">www.nice.org.uk/TA276</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP3492-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/tobramycin\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75687\" title=\"Solution for injection\" namespace=\"/drugs/tobramycin/solution-for-injection\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75716\" title=\"Inhalation powder\" namespace=\"/drugs/tobramycin/inhalation-powder\">Inhalation powder</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75709\" title=\"Nebuliser liquid\" namespace=\"/drugs/tobramycin/nebuliser-liquid\">Nebuliser liquid</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75702\" title=\"Eye drops\" namespace=\"/drugs/tobramycin/eye-drops\">Eye drops</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP88007\" namespace=\"/drugs/dexamethasone-with-tobramycin\" title=\"DEXAMETHASONE WITH TOBRAMYCIN\" count=\"1\" rel=\"backlink\">DEXAMETHASONE WITH TOBRAMYCIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78541\" namespace=\"/treatment-summaries/eye-infections-of\" title=\"Eye, infections of\" count=\"2\" rel=\"backlink\">Eye, infections of</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78593\" namespace=\"/treatment-summaries/aminoglycosides\" title=\"Aminoglycosides\" count=\"4\" rel=\"backlink\">Aminoglycosides</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_136\" namespace=\"/interactions/list-of-drug-interactions/antibacterials/aminoglycosides/tobramycin\" title=\"Tobramycin\" count=\"1\" rel=\"link\">Tobramycin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34544\" namespace=\"/drug-classes/aminoglycosides\" title=\"AMINOGLYCOSIDES\" count=\"1\" rel=\"link\">AMINOGLYCOSIDES</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75687\" namespace=\"/drugs/tobramycin/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75716\" namespace=\"/drugs/tobramycin/inhalation-powder\" title=\"Inhalation powder\" count=\"1\" rel=\"link\">Inhalation powder</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75709\" namespace=\"/drugs/tobramycin/nebuliser-liquid\" title=\"Nebuliser liquid\" count=\"1\" rel=\"link\">Nebuliser liquid</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75702\" namespace=\"/drugs/tobramycin/eye-drops\" title=\"Eye drops\" count=\"1\" rel=\"link\">Eye drops</xref>\n</links>\n</topic>",
    "id": "PHP3492",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/tobramycin",
    "basename": "tobramycin",
    "title": "TOBRAMYCIN",
    "interactants": [
        {
            "id": "bnf_int_136",
            "label": "Tobramycin"
        }
    ],
    "vtmid": "89695009",
    "drugClassification": [
        "Aminoglycosides"
    ],
    "inheritsFromClass": [
        "AMINOGLYCOSIDES"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Local treatment of infections",
                        "html": "Local treatment of infections"
                    }
                ],
                "specificity": {
                    "routes": [
                        "To the eye"
                    ],
                    "textContent": "To the eye",
                    "html": "To the eye"
                },
                "child": [
                    {
                        "textContent": "Apply twice daily for 6&#8211;8 days.",
                        "html": "<p>Apply twice daily for 6&#8211;8 days.</p>",
                        "ageGroup": "1&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Apply twice daily for 6&#8211;8 days.",
                        "html": "<p>Apply twice daily for 6&#8211;8 days.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Local treatment of infections (severe infection)",
                        "html": "Local treatment of infections (severe infection)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "To the eye"
                    ],
                    "textContent": "To the eye",
                    "html": "To the eye"
                },
                "child": [
                    {
                        "textContent": "Apply 4 times a day for first day, then apply twice daily for 5&#8211;7 days.",
                        "html": "<p>Apply 4 times a day for first day, then apply twice daily for 5&#8211;7 days.</p>",
                        "ageGroup": "1&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Apply 4 times a day for first day, then apply twice daily for 5&#8211;7 days.",
                        "html": "<p>Apply 4 times a day for first day, then apply twice daily for 5&#8211;7 days.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Septicaemia",
                        "html": "Septicaemia"
                    },
                    {
                        "textContent": "Meningitis and other CNS infections",
                        "html": "Meningitis and other CNS infections"
                    },
                    {
                        "textContent": "Biliary-tract infection",
                        "html": "Biliary-tract infection"
                    },
                    {
                        "textContent": "Acute pyelonephritis or prostatitis",
                        "html": "Acute pyelonephritis or prostatitis"
                    },
                    {
                        "textContent": "Pneumonia in hospital patients",
                        "html": "Pneumonia in hospital patients"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection or slow intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By intramuscular injection or by slow intravenous injection or by intravenous infusion",
                    "html": "By intramuscular injection or by slow intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "3 mg/kg daily in 3 divided doses; increased if necessary up to 5 mg/kg daily in 3&#8211;4 divided doses, increased dose used in severe infection; dose to be reduced back to 3 mg/kg as soon as clinically indicated.",
                        "html": "<p>3&#8239;mg/kg daily in 3 divided doses; increased if necessary up to 5&#8239;mg/kg daily in 3&#8211;4 divided doses, increased dose used in severe infection; dose to be reduced back to 3&#8239;mg/kg as soon as clinically indicated.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Urinary-tract infection",
                        "html": "Urinary-tract infection"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "2&#8211;3 mg/kg for 1 dose.",
                        "html": "<p>2&#8211;3&#8239;mg/kg for 1 dose.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis",
                        "html": "Chronic <ph outputclass=\"organism\"> <i>Pseudomonas aeruginosa</i> </ph> infection in patients with cystic fibrosis",
                        "organism": "Pseudomonas aeruginosa"
                    }
                ],
                "specificity": {
                    "routes": [
                        "inhalation of powder"
                    ],
                    "textContent": "By inhalation of powder",
                    "html": "By inhalation of powder",
                    "organism": "Pseudomonas aeruginosa"
                },
                "adult": [
                    {
                        "textContent": "300 mg every 12 hours for 28 days, subsequent courses repeated after 28-day interval without tobramycin nebuliser solution.",
                        "html": "<p>300&#8239;mg every 12&#8239;hours for 28 days, subsequent courses repeated after 28-day interval without tobramycin nebuliser solution.</p>"
                    },
                    {
                        "textContent": "112 mg every 12 hours for 28 days, subsequent courses repeated after 28-day interval without tobramycin inhalation powder.",
                        "html": "<p>112&#8239;mg every 12&#8239;hours for 28 days, subsequent courses repeated after 28-day interval without tobramycin inhalation powder.</p>"
                    }
                ]
            }
        ],
        "extremesOfBodyWeight": [
            {
                "type": "extremesOfBodyWeight",
                "title": "Doses at extremes of body-weight",
                "textContent": "To avoid excessive dosage in obese patients, use ideal weight for height to calculate parental dose and monitor serum-tobramycin concentration closely.",
                "html": "<p>To avoid excessive dosage in obese patients, use ideal weight for height to calculate parental dose and monitor serum-tobramycin concentration closely.</p>"
            }
        ]
    },
    "cautions": {
        "cautionsOrContraindicationsWithRoutes": [
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "severe haemoptysis&#8212;risk of further haemorrhage",
                "html": "severe haemoptysis&#8212;risk of further haemorrhage",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by inhalation",
                    "routes": [
                        "inhalation"
                    ]
                }
            }
        ]
    },
    "sideEffects": {
        "specific": {
            "frequencies": {
                "uncommon": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "rash in adults",
                        "html": "rash in adults",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "With intramuscular use",
                            "html": "With intramuscular use",
                            "routes": [
                                "intramuscular"
                            ],
                            "patientType": "adults"
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "bronchospasm",
                        "html": "bronchospasm",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "cough (more frequent by inhalation of powder)",
                        "html": "cough (more frequent by inhalation of powder)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "dysphonia",
                        "html": "dysphonia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "epistaxis",
                        "html": "epistaxis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "haemoptysis",
                        "html": "haemoptysis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "laryngitis",
                        "html": "laryngitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "mouth ulcers",
                        "html": "mouth ulcers",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "pharyngitis",
                        "html": "pharyngitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "salivary hypersecretion",
                        "html": "salivary hypersecretion",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "taste disturbances",
                        "html": "taste disturbances",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    }
                ]
            }
        }
    },
    "monitoringRequirements": {
        "therapeuticDrugMonitoring": [
            {
                "type": "therapeuticDrugMonitoring",
                "specificity": {
                    "textContent": "With intravenous use in neonates",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in neonates",
                    "patientType": "neonates",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Extended interval dose regimen in neonates: pre-dose (&#8216;trough&#8217;) concentration should be less than 2 mg/litre.",
                "html": "<p>\n<i>Extended interval dose regimen in neonates</i>: pre-dose (&#8216;trough&#8217;) concentration should be less than 2&#8239;mg/litre.</p>"
            },
            {
                "type": "therapeuticDrugMonitoring",
                "specificity": {
                    "textContent": "With intravenous use in children",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Once daily dose regimen: pre-dose (&#8216;trough&#8217;) concentration should be less than 1 mg/litre.\n\nMultiple daily dose regimen: one-hour (&#8216;peak&#8217;) serum concentration should not exceed 10 mg/litre (8&#8211;12 mg/litre in cystic fibrosis); pre-dose (&#8216;trough&#8217;) concentration should be less than 2 mg/litre.",
                "html": "<p>\n<i>Once daily dose regimen</i>: pre-dose (&#8216;trough&#8217;) concentration should be less than 1&#8239;mg/litre.</p><p>\n<i>Multiple daily dose regimen</i>: one-hour (&#8216;peak&#8217;) serum concentration should not exceed 10&#8239;mg/litre (8&#8211;12&#8239;mg/litre in cystic fibrosis); pre-dose (&#8216;trough&#8217;) concentration should be less than 2&#8239;mg/litre.</p>"
            },
            {
                "type": "therapeuticDrugMonitoring",
                "specificity": {
                    "textContent": "With intramuscular use or intravenous use in adults",
                    "html": "With <ph outputclass=\"route\">intramuscular</ph> use or <ph outputclass=\"route\">intravenous</ph> use in adults",
                    "patientType": "adults",
                    "routes": [
                        "intramuscular",
                        "intravenous"
                    ]
                },
                "textContent": "One-hour (&#8216;peak&#8217;) serum concentration should not exceed 10 mg/litre; pre-dose (&#8216;trough&#8217;) concentration should be less than 2 mg/litre.",
                "html": "<p>One-hour (&#8216;peak&#8217;) serum concentration should not exceed 10&#8239;mg/litre; pre-dose (&#8216;trough&#8217;) concentration should be less than 2&#8239;mg/litre.</p>"
            }
        ],
        "patientParameters": [
            {
                "type": "patientParameters",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by <ph outputclass=\"route\">inhalation</ph>",
                    "routes": [
                        "inhalation"
                    ]
                },
                "textContent": "Measure lung function before and after initial dose of tobramycin and monitor for bronchospasm; if bronchospasm occurs in a patient not using a bronchodilator, repeat test using bronchodilator.\n\nMonitor renal function before treatment and then annually.",
                "html": "<p>Measure lung function before and after initial dose of tobramycin and monitor for bronchospasm; if bronchospasm occurs in a patient not using a bronchodilator, repeat test using bronchodilator.</p><p>Monitor renal function before treatment and then annually.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in children",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion, dilute with Glucose 5% or Sodium Chloride 0.9%; give over 20&#8211;60 minutes.",
                "html": "<p>For <i>intravenous infusion</i>, dilute with Glucose 5% or Sodium Chloride 0.9%; give over 20&#8211;60 minutes.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in adults",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in adults",
                    "patientType": "adults",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Nebcin ); intermittent or via drip tubing in Glucose 5% or Sodium chloride 0.9%.\n\nFor adult intermittent infusion suggested volume 50&#8211;100 mL given over 20&#8211;60 minutes.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Nebcin</i>\n<tm tmtype=\"reg\"/>); intermittent or via drip tubing in Glucose 5% or Sodium chloride 0.9%.</p><p>For adult intermittent infusion suggested volume 50&#8211;100&#8239;mL given over 20&#8211;60 minutes.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by <ph outputclass=\"route\">inhalation</ph>",
                    "routes": [
                        "inhalation"
                    ]
                },
                "textContent": "Other inhaled drugs should be administered before tobramycin.",
                "html": "<p>Other inhaled drugs should be administered before tobramycin.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "specificity": {
                    "textContent": "With intravenous use or when used by inhalation in children",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use or when used by <ph outputclass=\"route\">inhalation</ph> in children",
                    "patientType": "children",
                    "routes": [
                        "intravenous",
                        "inhalation"
                    ]
                },
                "textContent": "Local guidelines may vary in dosing advice provided.",
                "html": "<p>Local guidelines may vary in dosing advice provided.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by <ph outputclass=\"route\">inhalation</ph>",
                    "routes": [
                        "inhalation"
                    ]
                },
                "textContent": "Patient counselling is advised for Tobramycin dry powder for inhalation (administration).",
                "html": "<p>Patient counselling is advised for Tobramycin dry powder for inhalation (administration).</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA276",
                        "label": "www.nice.org.uk/TA276"
                    }
                ],
                "fundingIdentifier": "NICE TA276",
                "textContent": "When used by inhalation Tobramycin by dry powder inhalation for pseudomonal lung infection in cystic fibrosis (March 2013) Tobramycin dry powder for inhalation is recommended for chronic pulmonary infection caused by Pseudomonas aeruginosa in patients with cystic fibrosis only if there is an inadequate response to colistimethate sodium, or if colistimethate sodium cannot be used because of contra-indications or intolerance. The manufacturer must provide tobramycin dry powder for inhalation at the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS. Patients currently receiving tobramycin dry powder for inhalation can continue treatment until they and their clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA276",
                "html": "<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph> </p> <p outputclass=\"title\">Tobramycin by dry powder inhalation for pseudomonal lung infection in cystic fibrosis (March 2013)</p> <p>Tobramycin dry powder for inhalation is recommended for chronic pulmonary infection caused by <ph outputclass=\"organism\"> <i>Pseudomonas aeruginosa</i> </ph> in patients with cystic fibrosis only if there is an inadequate response to colistimethate sodium, or if colistimethate sodium cannot be used because of contra-indications or intolerance. The manufacturer must provide tobramycin dry powder for inhalation at the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS.</p> <p>Patients currently receiving tobramycin dry powder for inhalation can continue treatment until they and their clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA276\">www.nice.org.uk/TA276</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75687",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75716",
                "label": "Inhalation powder",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75709",
                "label": "Nebuliser liquid",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75702",
                "label": "Eye drops",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP88007",
                "label": "DEXAMETHASONE WITH TOBRAMYCIN",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78541",
                "label": "Eye, infections of",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78593",
                "label": "Aminoglycosides",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_136",
                "label": "Tobramycin",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34544",
                "label": "AMINOGLYCOSIDES",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75687",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75716",
                "label": "Inhalation powder",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75709",
                "label": "Nebuliser liquid",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75702",
                "label": "Eye drops",
                "type": "medicinalForm"
            }
        ]
    }
}